首页> 美国卫生研究院文献>Journal of Clinical and Translational Science >2516 Ultra-low Na18F tracer dosing for preclinical skeletal imaging enables new concepts in digital PET/CT
【2h】

2516 Ultra-low Na18F tracer dosing for preclinical skeletal imaging enables new concepts in digital PET/CT

机译:用于临床前骨骼成像的2516超低Na18F示踪剂剂量可在数字PET / CT中实现新概念

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVES/SPECIFIC AIMS: The aim of this study was to assess the ultra-dose Na18F dPET protocol feasibility for skeleton imaging in a canine model with reduced radiation dose and preserved quantitative characteristics. We hypothesized that administering an ultra-low Na18F dose would provide suitable image quality while reducing subject’s exposure to radiation. METHODS/STUDY POPULATION: In total, 13 adult male beagles [weight (kg) mean±SD; 14.3±2.2] were scanned. The dogs were administered 3 different Na18F doses: 3 (standard dose/SD), 1 (low dose/LD), and 0.05 (ultra-low dose/ULD) mCi. Imaging started ≃45 minutes post injection for ≃ 33 minute total acquisition time. Covering the whole body, 11 bed positions, acquiring 120 (3 mCi) and 180 (1, 0.05 mCi) seconds per bed position. All imaging was performed on a digital photon counting system (Philips Vereos, pre-commercial release). PET list mode data were reconstructed using Time-of-flight with 4, 2, and 1 mm3 voxel volumes. Point spread function, and Gaussian filtering were applied. Two experienced blinded readers evaluated image sets overall quality, tissue characterization, and quality of background in the whole body skeleton. Three-dimensional (3D) regions of interest (ROI) were traced over the distal femur, first lumbar vertebra, and a portion of the liver, recording standard uptake values (SUVmax and SUVmean). RESULTS/ANTICIPATED RESULTS: All the scans and reconstructions were successfully completed in all subjects. Decreasing Na18F dose from the standard dose (3 mCi) to the ultra-low dose/ULDO (0.05 mCi), demonstrated acceptable image quality and quantification. Ultra-low dose Na18F SUVmean values for the 3D ROIs reported (mean±SD) 2.6±0.7, 2.5±1.1, 9±1.6, and 0.6±0.3 from the right and left distal femur, first lumbar vertebra, and a portion of the liver, respectively. When compared the SD with the LD and ULD, dPET demonstrated acceptable image quality and definition for qualitative overall assessment. This was also found for the overall quantitative ROI assessment of the healthy canine skeletons. DISCUSSION/SIGNIFICANCE OF IMPACT: Ultra-low dose Na18F at a level of 50 μCi for a 14 kg canine appears to be diagnostically feasible and a robust option to reduce (60-fold) radiotracer doses in a translational animal model using a dPET system. Furthermore, it allows us to move preclinical nuclear medicine imaging forward with substantial reduced exposure levels while preserving image quality. Both visual and quantitative results indicate that the standard-dose bone Na18F dPET can be decreased with a satisfactory diagnostic image quality. Ultra-low Na18F dose is indeed important for younger populations, control patients, and nononcological diseases/conditions. Favorable pharmacokinetics of Na18F (such as high bone uptake, minimal binding to serum proteins, rapid single-pass extraction, and fast clearance from the soft tissues) in addition to the technological capabilities of dPET/CT demonstrated feasibility enabling dose reduction strategies. Ultra-low dose has diagnostic reproducibility and lower radiation burden compared with higher fixed dose techniques in current available guidelines [Society of Nuclear Medicine and Molecular Imaging; SNMMI (5–10 mCi)]. Na18F dPET/CT provides higher sensitivity and diagnostic accuracy, which enables high-quality images with lower tracer activity in this translational animal model. Future research will apply the same methodology to other anatomical targets as well as to the use of different tracers. Preclinical nuclear medicine imaging using ultra-low tracer doses, demonstrated the potential to obtain reasonable quality images and diminishing radiation surveillance in accordance with as low as reasonably achievable tracer levels.
机译:目的/特定目的:这项研究的目的是评估超剂量的Na18F dPET协议在减少辐射剂量和保留定量特征的犬模型中进行骨骼成像的可行性。我们假设,使用超低的Na18F剂量可以提供合适的图像质量,同时减少受试者的辐射暴露。方法/研究人群:总共13只成年雄性比格犬(体重(kg)平均值±SD; 14.3±2.2]被扫描。给狗施用3种不同的Na18F剂量:3(标准剂量/ SD),1(低剂量/ LD)和0.05(超低剂量/ ULD)mCi。成像在注射后minutes45分钟开始,总共≃33分钟。覆盖整个11个床位,每个床位获得120(3 mCi)和180(1,0.05 mCi)秒。所有成像均在数字光子计数系统(Philips Vereos,商业发布)上进行。使用飞行时间以4、2和1 mm 3 体素体积重建PET列表模式数据。应用了点扩散函数和高斯滤波。两位经验丰富的盲人读者评估了图像集的整体质量,组织特征以及整个人体骨骼的背景质量。在股骨远端,第一腰椎和部分肝脏上追踪感兴趣的三维(3D)区域,记录标准摄取值(SUVmax和SUVmean)。结果/预期结果:所有受试者的所有扫描和重建均成功完成。将Na18F剂量从标准剂量(3 mCi)降低到超低剂量/ ULDO(0.05 mCi),证明了可接受的图像质量和定量。报告的3D ROI的超低剂量Na18F SUV平均值(平均值±SD)分别从左右股骨远端,左腰椎以及部分腰椎2.6±0.7、2.5±1.1、9±1.6和0.6±0.3肝分别。当将SD与LD和ULD进行比较时,dPET表现出可接受的图像质量和清晰的定性总体评估。在健康犬骨骼的整体定量ROI评估中也发现了这一点。讨论/意义:对于14 kg犬,50μCi水平的超低剂量Na18F似乎在诊断上是可行的,并且是使用dPET系统在平移动物模型中减少(60倍)放射性示踪剂量的可靠选择。此外,它使我们能够在保持图像质量的同时,大幅降低暴露水平,从而推动临床前核医学成像的发展。视觉和定量结果均表明,标准剂量的骨Na18F dPET可以降低,并具有令人满意的诊断图像质量。 Na18F的超低剂量确实对年轻的人群,对照患者和非肿瘤疾病/病症非常重要。除了dPET / CT的技术能力外,Na18F的良好药代动力学(例如高骨吸收,与血清蛋白的结合极少,快速单次提取以及从软组织中快速清除)证明了可行的降低剂量策略的可行性。与当前可用指南中的更高的固定剂量技术相比,超低剂量具有诊断重现性,并且辐射负荷更低[核医学与分子影像学会; SNMMI(5–10 mCi)]。 Na18F dPET / CT可提供更高的灵敏度和诊断准确性,从而可以在此转化动物模型中以较低的示踪剂活性获得高质量的图像。未来的研究将把相同的方法应用于其他解剖目标以及使用不同的示踪剂。使用超低示踪剂剂量的临床前核医学成像证明,按照尽可能低的示踪剂水平获得合理质量的图像并减少放射监测的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号